Adalimumab biosimilar (Tonghua Dongbao Pharmaceutical)

阿达木单抗生物类似药（通化东宝）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (Tonghua Dongbao Pharmaceutical)
Drug Alias NameRecombinant human anti-tumour necrosis factor alpha (TNF-α) monoclonal antibody (Tonghua Dongbao Pharmaceutical)阿达木单抗生物仿制药（通化东宝）重组抗肿瘤坏死因子-α全人源单抗（通化东宝）重组抗TNFa全人单抗（通化东宝）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTonghua Dongbao Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTonghua Dongbao Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A